Drug Approval | May 01, 2026
Dr Reddy’s becomes first to secure Health Canada nod for generic Semaglutide injection
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
The deal, backed by healthcare investor ARCHIMED, signals a major push to accelerate connected, patient-centered cardiac care worldwide
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
The agreement could rise to $900 million if key commercial milestones are met
Company to highlight science-backed actives, nature-powered ingredients, and its new “Natural by Barentz” private label platform in Barcelona
Backed by ARCHIMED, the deal strengthens connected cardiac diagnostics with integrated Holter, ABPM, and telemedicine solutions
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
Subscribe To Our Newsletter & Stay Updated
